Bicocca Open Archive

Logo unimib boa
ALIBERTI, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.923
AS - Asia 5.412
EU - Europa 4.807
SA - Sud America 878
AF - Africa 133
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 4
Totale 23.176
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.337
SG - Singapore 1.940
CN - Cina 1.284
IT - Italia 826
HK - Hong Kong 794
DE - Germania 741
RU - Federazione Russa 732
BR - Brasile 681
VN - Vietnam 606
SE - Svezia 593
UA - Ucraina 542
CA - Canada 514
IE - Irlanda 471
GB - Regno Unito 222
FR - Francia 216
IN - India 154
FI - Finlandia 152
BD - Bangladesh 133
AT - Austria 112
AR - Argentina 79
KR - Corea 61
ID - Indonesia 57
TR - Turchia 57
NL - Olanda 48
IQ - Iraq 47
ZA - Sudafrica 46
PK - Pakistan 41
MX - Messico 39
SA - Arabia Saudita 38
JP - Giappone 35
CO - Colombia 28
CZ - Repubblica Ceca 28
EC - Ecuador 27
ES - Italia 24
PH - Filippine 24
PL - Polonia 24
UZ - Uzbekistan 23
DK - Danimarca 17
EG - Egitto 17
VE - Venezuela 17
BE - Belgio 13
CL - Cile 13
NP - Nepal 12
MY - Malesia 11
PE - Perù 11
AU - Australia 10
PY - Paraguay 10
TN - Tunisia 10
AE - Emirati Arabi Uniti 9
JO - Giordania 9
KE - Kenya 9
LB - Libano 9
NZ - Nuova Zelanda 9
TH - Thailandia 9
AL - Albania 8
DZ - Algeria 8
KZ - Kazakistan 8
MA - Marocco 8
PS - Palestinian Territory 8
UY - Uruguay 8
AZ - Azerbaigian 7
ET - Etiopia 7
TT - Trinidad e Tobago 7
CR - Costa Rica 6
IL - Israele 6
JM - Giamaica 6
TW - Taiwan 6
BG - Bulgaria 5
CH - Svizzera 5
HN - Honduras 5
IR - Iran 5
PT - Portogallo 5
RO - Romania 5
GR - Grecia 4
MD - Moldavia 4
OM - Oman 4
SN - Senegal 4
BO - Bolivia 3
DO - Repubblica Dominicana 3
KG - Kirghizistan 3
KH - Cambogia 3
KW - Kuwait 3
LT - Lituania 3
NG - Nigeria 3
PA - Panama 3
BH - Bahrain 2
BW - Botswana 2
BY - Bielorussia 2
CG - Congo 2
CI - Costa d'Avorio 2
EU - Europa 2
LY - Libia 2
MU - Mauritius 2
MZ - Mozambico 2
NO - Norvegia 2
SC - Seychelles 2
SV - El Salvador 2
ZW - Zimbabwe 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
Totale 23.162
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.381
Woodbridge 1.161
Singapore 1.068
Ashburn 926
Fairfield 865
Hong Kong 788
Houston 778
Jacksonville 565
San Jose 527
Dublin 460
Chandler 456
Wilmington 366
Seattle 352
Dearborn 346
Toronto 333
Cambridge 302
Frankfurt am Main 270
Milan 263
New York 249
Beijing 240
Princeton 225
Ho Chi Minh City 185
Chicago 178
The Dalles 145
Los Angeles 140
Santa Clara 131
Hanoi 123
Nanjing 119
Hangzhou 110
Altamura 108
Shanghai 99
Vienna 98
Lachine 97
Lauterbourg 97
Lawrence 95
Moscow 84
Dallas 76
São Paulo 63
Buffalo 61
Council Bluffs 61
Rome 59
Hefei 57
Seoul 57
Nanchang 46
Helsinki 45
San Diego 39
Shenyang 34
Ottawa 31
Dong Ket 30
Hebei 29
Jiaxing 28
Orem 28
Jakarta 27
London 27
Munich 27
Rio de Janeiro 27
Dhaka 25
Guangzhou 25
Brno 23
Haiphong 23
Jinan 23
Salt Lake City 23
Andover 22
Norwalk 22
Tokyo 22
Tianjin 21
Boardman 20
Changsha 20
Da Nang 20
Falls Church 20
Tashkent 19
Amsterdam 18
Brooklyn 18
Montreal 18
Warsaw 18
Jeddah 17
Ningbo 17
Phoenix 17
Mountain View 16
Tampa 15
Baghdad 14
Chennai 14
Fremont 14
Huizen 14
Belo Horizonte 13
Columbus 13
Riyadh 13
Johannesburg 12
New Delhi 12
Newark 12
Redondo Beach 12
San Francisco 12
Atlanta 11
Brussels 11
Denver 11
Hải Dương 11
Kunming 11
Lahore 11
Miami 11
Naples 11
Totale 15.307
Salva come PNG Salva come JPEG
Nome #
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 412
Delirium symptoms during hospitalization predict long-term mortality in patients with severe pneumonia 376
Clinical phenotypes in adult patients with bronchiectasis 333
Positive end expiratory pressure in acute hypoxemic respiratory failure due to community acquired pneumonia: Do we need a personalized approach? 316
Impact of age and comorbidity on cause and outcome in community-acquired pneumonia 313
Cardiovascular autonomic alterations in hospitalized patients with community-acquired pneumonia 309
Dyspnea in crackling lungs 308
Non-invasive mechanical ventilation in patients with diffuse interstitial lung diseases 307
Impact of traffic-related air pollution on pulmonary oxidative stress 304
Non-tuberculous mycobacteria pulmonary disease: an integrated approach beyond antibiotics 296
A 61-year-old female with chronic cough and purulent sputum 293
Multidimensional severity assessment in bronchiectasis: An analysis of seven European cohorts 291
Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: A multinational point prevalence study of hospitalised patients 289
Influenza A/H1N1 severe pneumonia: Novel morphocytological findings in bronchoalveolar lavage 280
Etiology of non-cystic fibrosis bronchiectasis in adults and its correlation to disease severity 279
Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community-acquired pneumonia 273
Phenotyping in Bronchiectasis: Are we moving towards a personalized medicine? 269
Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study 268
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 265
The management of community-acquired pneumonia in the elderly 252
A 13-year-old female with shortness of breath and pleuritic chest pain 250
Diaphragm ultrasonography in the management of patients with amyotrophic lateral sclerosis 249
Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study 248
Prulifloxacin: A brief review of its potential in the treatment of acute exacerbation of chronic bronchitis 247
Mortality in acute cardiogenic pulmonary edema treated with continuous positive airway pressure 247
Geriatric multidimensional assessment for elderly patients with acute respiratory diseases 247
Individualizing duration of antibiotic therapy in community-acquired pneumonia 245
Hospital admission decision for patients with community-acquired pneumonia 243
Serum and exhaled breath condensate inflammatory cytokines in community-acquired pneumonia: a prospective cohort study 243
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 241
Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study 241
Mixed community-acquired lower respiratory tract infections 235
International prevalence and risk factors evaluation for drug-resistant Streptococcus pneumoniae pneumonia 231
Early administration of the first antimicrobials should be considered a marker of optimal care of patients with community-acquired pneumonia rather than a predictor of outcomes 228
Non-invasive continuous positive airway pressure in monolateral lung transplant patient with pneumonia and IPF 225
The Clinical and Economic Impact of Exacerbations of Chronic Obstructive Pulmonary Disease: A Cohort of Hospitalized Patients 224
Helmet CPAP vs. oxygen therapy in severe hypoxemic respiratory failure due to pneumonia 224
Do prognostic factors help physicians in predicting legionellosis' respiratory complications? 221
Microbiological Diagnosis and Antibiotic Therapy in Patients with Community-Acquired Pneumonia and Acute COPD Exacerbation in Daily Clinical Practice: Comparison to Current Guidelines 220
Are multi-drug resistant (MDR) pathogens related to higher mortality in pneumonia? 219
Azithromycin and lower respiratory tract infections 218
Chlamydophila pneumoniae 218
Acute myocardial infarction versus other cardiovascular events in communityacquired pneumonia 217
Chlamydia pneumoniae and acute aortic syndrome: A call for a multi-institutional study 216
The bronchiectasis severity index. An international derivation and validation study 215
Pneumonia: how important are local epidemiology and smoking habits? 214
Long-term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy 212
Contrasting Inflammatory Responses in Severe and Non-severe Community-acquired Pneumonia 212
Strategic targets of essential host-pathogen interactions 211
The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia 211
Stratifying Risk Factors for Multidrug-Resistant Pathogens in Hospitalized Patients Coming From the Community With Pneumonia 209
Acidemia does not affect outcomes of patients with acute cardiogenic pulmonary edema treated with continuous positive airway pressure 208
Criteria for clinical stability in hospitalised patients with community-acquired pneumonia 206
Thrombocytopenia and thrombocytosis at time of hospitalization predict mortality in patients with community-acquired pneumonia 205
Early application of non-invasive continuous positive airway pressure in acute respiratory distress syndrome due to a drug overdose: a case report 203
Noninvasive ventilation or continuous positive airway pressure in pulmonary edema patients with respiratory acidosis? Look at the bicarbonates 203
Usefulness of simplified acute physiology score II in predicting mortality in patients admitted to an emergency medicine ward 202
100 years of respiratory medicine: pneumonia 200
Incidence, etiology, timing, and risk factors for clinical failure in hospitalized patients with community-acquired pneumonia 199
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia 199
Clinical and economical impact of exacerbations of chronic obstructive pulmonary disease (COPD): a two year study 199
Should health care systems and health care providers implement a new pathway for hospitalized patients with community-acquired pneumonia? 199
Non-invasive-ventilation in H1N1 acute respiratory failure in emergency department: A case series 199
Compliance with anti-H1N1 vaccine among healthcare workers and general population 198
COPD and bronchiectasis: Phenotype, endotype or co-morbidity? 196
Validation of the 3CPO-score in a prospective cohort of Acute Cardiogenic Pulmonary Edema (ACPE) patients 194
Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis 193
The effectiveness of the polysaccharide pneumococcal vaccine for the prevention of hospitalizations due to Streptococcus pneumoniae community-acquired pneumonia in the elderly differs between the sexes: results from the Community-Acquired Pneumonia Organization (CAPO) international cohort study 188
Predicting Mycobacterium tuberculosis in patients with community-acquired pneumonia 187
Association between time to clinical stability and outcomes after discharge in hospitalized patients with community-acquired pneumonia 186
Pneumonia in the community caused by multidrug-resistant organisms: keep working on probabilistic scores 186
The management of patients with community-acquired pneumonia beyond antibiotic therapy 183
“Normotension” on admission to the emergency department affects outcome of patients with acute cardiogenic pulmonary edema (ACPE) 183
Acute myocardial infarction in hospitalized patients with community-acquired pneumonia 181
Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia 179
Impact of exacerbations in the natural course of COPD 179
The role of biomarkers in low respiratory tract infections 179
Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection 178
The pneumonia severity index and the CRB-65 in cancer patients with community-acquired pneumonia 177
Antibiotics as immunomodulant agents in COPD 177
Acute exacerbation of COPD: application of evidence-based guidelines 176
Is it time for a "pneumo-geriatrician" for frail old patients with respiratory diseases? 175
Highlights on the appropriate use of fluoroquinolones in respiratory tract infections 174
Chlamydia pneumoniae and Mycoplasma pneumoniae 174
Management of nontuberculous mycobacterial infection in the elderly 174
Clinical Stability versus Clinical Failure in Patients with Community-Acquired Pneumonia 172
Healthcare-associated pneumonia: where do we go next? 171
Telithromycin in lower respiratory tract infections 170
Clinical applications of azithromycin microspheres in respiratory tract infections 170
Cardiac diseases complicating community-acquired pneumonia 169
Pneumococcal Vaccine and Patients with Pulmonary Diseases 168
Acute effects of positive end-expiratory pressure on left ventricle diastolic function in healthy subjects 167
Understanding the roles of cytokines and neutrophil activity and neutrophil apoptosis in the protective versus deleterious inflammatory response in pneumonia 163
Where are the acutely ill best cared for and who should look after them? 161
The role of neutropenia on outcomes of cancer patients with community-acquired pneumonia 159
Clinical failure in hospitalized patients with community acquired pneumonia (CAP): Preliminary results from the FAILCAP study 155
Predicting mortality in hospitalized patients with 2009 H1N1 influenza pneumonia 154
Early outcomes in CAP: Clinical stability, clinical failure and nonresolving pneumonia 152
Bronchiectasis: An update 151
Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective 151
Totale 21.986
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.791
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.791
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021127 0 0 0 0 0 0 0 0 0 0 0 127
2021/20221.059 51 102 104 90 52 103 55 61 64 86 93 198
2022/20231.833 250 532 224 133 92 315 9 90 133 4 25 26
2023/20241.249 35 32 47 31 172 335 254 57 153 15 10 108
2024/20252.827 205 348 76 141 275 60 82 79 313 474 326 448
2025/20267.557 694 427 538 874 777 401 999 442 626 685 503 591
Totale 23.406